Details for Patent: 10,403,170

Which drugs does patent 10,403,170 protect, and when does it expire?

Patent 10,403,170 protects CONTRAVE and is included in one NDA.

This patent has sixty-one patent family members in thirty-three countries.

Summary for Patent: 10,403,170

Title:	Methods of treating overweight and obesity
Abstract:	The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
Inventor(s):	Klassen; Preston (La Jolla, CA), Taylor; Kristin (San Diego, CA)
Assignee:	Nalpropion Pharmaceuticals, Inc. (Morristown, NJ)
Application Number:	15/491,870
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 10,403,170

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Nalpropion	CONTRAVE	bupropion hydrochloride; naltrexone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	200063-001	Sep 10, 2014		RX	Yes	Yes						FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY

International Family Members for US Patent 10,403,170

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	093694
Argentina	125234
Australia	2013271622
Australia	2018203271